This analysis of data from the Global Burden of Disease Study examines the extent of rotavirus infection and associated deaths among children younger than 5 years worldwide and whether the rotavirus vaccine has reduced the diarrhea-associated mortality.
BackgroundPostlicensure data has identified a causal link between rotavirus vaccines and intussusception in some settings. As rotavirus vaccines are introduced globally, monitoring intussusception will be crucial for ensuring safety of the vaccine programs.MethodsTo obtain updated information on background rates and clinical management of intussusception, we reviewed studies of intussusception in children <18 years of age published since 2002. We assessed the incidence of intussusception by month of life among children <1 year of age, seasonality, method of diagnosis, treatment, and case-fatality.FindingsWe identified 82 studies from North America, Asia, Europe, Oceania, Africa, Eastern Mediterranean, and Central & South America that reported a total of 44,454 intussusception events. The mean incidence of intussusception was 74 per 100,000 (range: 9–328) among children <1 year of age, with peak incidence among infants 5–7 months of age. No seasonal patterns were observed. A radiographic modality was used to diagnose intussusception in over 95% of the cases in all regions except Africa where clinical findings or surgery were used in 65% of the cases. Surgical rates were substantially higher in Africa (77%) and Central and South America (86%) compared to other regions (13–29%). Case-fatality also was higher in Africa (9%) compared to other regions (<1%). The primary limitation of this review relates to the heterogeneity in intussusception surveillance across different regions.ConclusionThis review of the intussusception literature from the past decade provides pertinent information that should facilitate implementation of intussusception surveillance for monitoring the postlicensure safety of rotavirus vaccines.
The increased diversity and differences in genotype dominance observed in states using RotaTeq (G12P[8]), and in states and territories using Rotarix (equine-like G3P[8] and G2P[4]), suggest that these vaccines exert different immunological pressures that influence the diversity of rotavirus strains circulating in Australia.
BackgroundA birth dose strategy using a neonatal rotavirus vaccine to target early
prevention of rotavirus disease may address remaining barriers to global
vaccine implementation.MethodsWe conducted a randomized, placebo-controlled trial in Indonesia to evaluate
the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) to prevent
rotavirus gastroenteritis. Healthy newborns received three doses of RV3-BB
administered in a neonatal schedule at 0-5 days, 8 and 14 weeks or infant
schedule at 8, 14 and 18 weeks, or placebo. Laboratory-confirmed rotavirus
gastroenteritis was graded using a modified Vesikari score. The primary
analysis was efficacy against severe rotavirus gastroenteritis from two
weeks after all doses to 18 months in the combined vaccine group (neonatal
and infant schedule) compared with placebo.ResultsVaccine efficacy against severe rotavirus gastroenteritis to 18 months was
63% in the combined vaccine group (95% CI 34, 80; p<0.001), 75% in the
neonatal vaccine group (95% confidence interval [CI] 44, 91; p<0.001) and
51% in the infant vaccine group (95% CI 7, 76; p=0.03) in the per protocol
analysis, with similar results in the intention-to-treat analysis. Vaccine
efficacy to 12 months was 94% in the neonatal vaccine group (95%CI 56, 99;
p=0.006). Vaccine take occurred in 78/83 (94%) in the neonatal vaccine group
and 83/84 (99%) in the infant vaccine group. The vaccine was well tolerated,
with similar incidence of adverse events in vaccine and placebo
recipients.ConclusionRV3-BB was efficacious, immunogenic and well-tolerated when administered in a
neonatal or infant schedule in Indonesia.
We found a similarly increased risk of IS after both vaccines, but the balance of benefits and risks at population level was highly favorable, a finding likely to extend to other settings despite varying incidence of IS and potentially higher morbidity and mortality from both gastroenteritis and IS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.